EquitySector - HealthcareVery High Risk
Regular
NAV (21-Nov-24)
Returns (Since Inception)
Fund Size
₹1,187 Cr
Expense Ratio
2.25%
ISIN
INF789F01695
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
28 Jun 1999
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+43.02%
+41.83% (Cat Avg.)
3 Years
+19.78%
+18.69% (Cat Avg.)
5 Years
+27.15%
+27.15% (Cat Avg.)
10 Years
+12.69%
+14.64% (Cat Avg.)
Since Inception
+15.26%
— (Cat Avg.)
Equity | ₹1,168.89 Cr | 98.47% |
Debt | ₹1.28 Cr | 0.11% |
Others | ₹16.84 Cr | 1.42% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹134.05 Cr | 11.29% |
Cipla Ltd | Equity | ₹69.93 Cr | 5.89% |
Ajanta Pharma Ltd | Equity | ₹63.86 Cr | 5.38% |
Dr Reddy's Laboratories Ltd | Equity | ₹55.49 Cr | 4.67% |
Gland Pharma Ltd | Equity | ₹43.97 Cr | 3.70% |
Glenmark Pharmaceuticals Ltd | Equity | ₹42.42 Cr | 3.57% |
Apollo Hospitals Enterprise Ltd | Equity | ₹42.14 Cr | 3.55% |
Fortis Healthcare Ltd | Equity | ₹39.63 Cr | 3.34% |
Procter & Gamble Health Ltd | Equity | ₹38.72 Cr | 3.26% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹36.43 Cr | 3.07% |
Suven Pharmaceuticals Ltd | Equity | ₹36.28 Cr | 3.06% |
Divi's Laboratories Ltd | Equity | ₹36.21 Cr | 3.05% |
Aurobindo Pharma Ltd | Equity | ₹34.91 Cr | 2.94% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹34.33 Cr | 2.89% |
Emcure Pharmaceuticals Ltd | Equity | ₹28.78 Cr | 2.42% |
Caplin Point Laboratories Ltd | Equity | ₹28.5 Cr | 2.40% |
Torrent Pharmaceuticals Ltd | Equity | ₹27.22 Cr | 2.29% |
Alkem Laboratories Ltd | Equity | ₹24.58 Cr | 2.07% |
Zydus Lifesciences Ltd | Equity | ₹24.56 Cr | 2.07% |
Metropolis Healthcare Ltd | Equity | ₹24.53 Cr | 2.07% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹21.75 Cr | 1.83% |
Sequent Scientific Ltd | Equity | ₹20.06 Cr | 1.69% |
Windlas Biotech Ltd | Equity | ₹19.56 Cr | 1.65% |
Pfizer Ltd | Equity | ₹19.37 Cr | 1.63% |
Ipca Laboratories Ltd | Equity | ₹18.99 Cr | 1.60% |
Jupiter Life Line Hospitals Ltd | Equity | ₹18.12 Cr | 1.53% |
Ami Organics Ltd | Equity | ₹17.8 Cr | 1.50% |
Marksans Pharma Ltd | Equity | ₹17.38 Cr | 1.46% |
Net Current Assets | Cash | ₹16.76 Cr | 1.41% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹16.03 Cr | 1.35% |
Syngene International Ltd | Equity | ₹15.48 Cr | 1.30% |
Vijaya Diagnostic Centre Ltd | Equity | ₹14.99 Cr | 1.26% |
Alembic Pharmaceuticals Ltd | Equity | ₹13.6 Cr | 1.15% |
Orchid Pharma Ltd | Equity | ₹12.88 Cr | 1.08% |
Star Health and Allied Insurance Co Ltd | Equity | ₹12.34 Cr | 1.04% |
Concord Biotech Ltd | Equity | ₹12.23 Cr | 1.03% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹11.72 Cr | 0.99% |
Indegene Ltd | Equity | ₹11.42 Cr | 0.96% |
Poly Medicure Ltd | Equity | ₹10.14 Cr | 0.85% |
Rainbow Childrens Medicare Ltd | Equity | ₹9.99 Cr | 0.84% |
Jubilant Pharmova Ltd | Equity | ₹4.99 Cr | 0.42% |
Global Health Ltd | Equity | ₹3.53 Cr | 0.30% |
364 Days T - Bill- 06/02/2025 | Bond - Gov't/Treasury | ₹1.28 Cr | 0.11% |
Clearing Corporation Of India Ltd. Std - Margin | Cash - Repurchase Agreement | ₹0.09 Cr | 0.01% |
Large Cap Stocks
32.82%
Mid Cap Stocks
26.60%
Small Cap Stocks
35.64%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹1,138.76 Cr | 95.93% |
Basic Materials | ₹17.8 Cr | 1.50% |
Financial Services | ₹12.34 Cr | 1.04% |
Standard Deviation
This fund
15.70%
Cat. avg.
15.67%
Lower the better
Sharpe Ratio
This fund
0.90
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Since May 2022
ISIN INF789F01695 | Expense Ratio 2.25% | Exit Load 1.00% | Fund Size ₹1,187 Cr | Age 25 years 4 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹28.64 Cr | 43.0% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹881.52 Cr | 37.2% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹881.52 Cr | 35.4% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹40.84 Cr | 37.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹208.21 Cr | 45.8% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹208.21 Cr | 43.1% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2770.21 Cr | 38.2% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2770.21 Cr | 36.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹852.28 Cr | 36.6% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.81 Cr | 37.0% |
Total AUM
₹3,26,312 Cr
Address
UTI Towers, Gn Block, Mumbai, 400 051
Your principal amount will be at Very High Risk